Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-ChOS in surgically resected pancreatic cancer
NCT02767752Phase 2Terminated
- Sponsor
- Herlev Hospital
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Oligosaccharide, Nutraceutical
- Countries
- 1
01
Overview
A Phase 2 trial of T-ChOS in pancreatic adenocarcinoma (PDAC), sponsored by Herlev Hospital. Started Nov 2016; status: terminated.
02
Drugs
T-ChOS
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02767752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767752.